Import Clearance and Shipment Permit

1. Key takeaways

Holding an MDMA and getting a shipment released at the border are two different things: the MDMA answers whether the device may circulate in Saudi Arabia, while MDS-REQ 5 (Shipments Clearance and Importation) answers whether this batch of goods may enter. The importer must be an in-country company holding a matching MDEL (Medical Device Establishment License), with a practical estimate of the licence fee range at SAR 5,000 to 25,000 plus 15% VAT. Imports of semi-finished medical devices for production purposes additionally require an import licence (see MDS-REQ 5). The SFDA lists the uses exempt from MDMA, including clinical trials, research, education, demonstration, training, custom purposes or national emergency use, but exemption from the MDMA is not exemption from import procedures. GRZAN’s reminder: clearance is obstructed when the MDMA is near expiry, and renewal is usually filed at least 90 days before expiry (practical estimate), so scheduling must reserve that window.

• Product compliance and batch compliance are separate judgements; clearance is assessed per shipment.
• The importer must hold a matching MDEL, practical estimate SAR 5,000 to 25,000 plus 15% VAT.
• Semi-finished devices imported for production need a separate import licence under MDS-REQ 5.
• MDMA-exempt uses are enumerated but still need import procedure compliance and proof of use.
• Goods supplied free of charge still fall under the Circulation definition and require clearance arrangements.

2. Legal basis

The table below lists the instruments cited for import clearance. Items marked as a practical estimate are pending verification against the SFDA website and GHAD billing.

3. Expert insights

1. Product compliance and batch compliance are two different judgements. The MDMA is judged against the product model, once and reusable; shipment release is judged against each specific batch, per consignment and never reusable. Under the same MDMA certificate, a batch can be held at the border because labels do not match the certificate, UDI-DI data is not in the database, storage and transport records are missing, or quantities exceed a reasonable range. The direct consequence for Chinese manufacturers is that clearance documents should be organized by batch, not by product. GRZAN recommends building a standard shipment pack: MDMA certificate and listing number, invoice and packing list, label artwork, UDI-DI data screenshots, storage and transport records, and authorization chain documents, assembled in the same order for every shipment to cut the time lost on per-consignment supplementing.

2. The MDMA-exempt use list has clear boundaries and does not exempt import procedures. The Note to Part 3 of MDS-G011 lists the uses exempt from MDMA: clinical trials, research, education, demonstration, training, custom purposes or national emergency use. This list establishes why goods may enter without an MDMA, but at the border it must still be provable that the batch genuinely belongs to one of the listed uses: clinical trial devices should correspond to a clinical trial approval under MDS-REQ 2, and demonstration or training devices should be able to explain their use scenario and subsequent disposal. Another frequently overlooked point: importing semi-finished medical devices for production purposes requires a separate import licence (see MDS-REQ 5). In other words, local assembly projects cannot skip import formalities on the assumption that semi-finished goods are not sold directly.

3. Goods supplied free of charge also fall within regulatory scope. Article 1 of Law M/54 defines Circulation as supplying devices or supplies with or without payment, whether for distribution or use. This means donations, exhibition samples, clinical trial supplies and after-sales replacement parts are not naturally exempt simply because no money changed hands. The practical consequence: exhibition items and donated goods also need corresponding import and release arrangements, otherwise they are treated at the border as uncertified products. GRZAN’s approach is to classify the circulation nature of the batch before shipping, whether sale, donation, exhibition sample or clinical supply, and then match the corresponding release path and document set, rather than reusing a normal trade template.

4. Clearance capability and registration scheduling must be planned together. Clearance is not a natural consequence of finished registration; it depends simultaneously on certificate status, UDI data status and importer licence status. Projects on the reliance pathway (MDS-G030 V1.0) have a review timeline of 35 to 60 working days, identical across the four risk classes, and that window covers technical review only; licensing, label implementation and UDI data entry still take time afterwards. GRZAN usually treats first-shipment clearance as an independent milestone scheduled backwards: from the planned shipping date minus clearance preparation time, derive the latest completion dates for MDMA approval, importer MDEL readiness and Saudi-DI data entry; MDMA renewal must be filed at least 90 days before expiry (practical estimate), which directly shapes the rhythm of continuous supply.

For how UDI data links to clearance documents, see https://www.grzan.cn/regulations/saudi/udi-and-saudi-di-database-37 ; for establishment licences and activity scopes, see https://www.grzan.cn/regulations/saudi/medical-device-establishment-licence-34 .

4. Practical recommendations

• Confirm the importing entity: check whether its MDEL activity scope covers the device categories and risk classes of this import (practical estimate SAR 5,000 to 25,000 plus 15% VAT).
• Build a standard shipment pack: MDMA certificate and listing number, invoice and packing list, label artwork, UDI-DI data screenshots, storage and transport records, and authorization chain documents, assembled in a fixed order.
• Batch-versus-certificate consistency check: before shipping, compare model, brand name and legal manufacturer name and address word for word with the certificate content.
• Classify special uses first: for clinical trials, research, education, demonstration, training, custom purposes or national emergency use, fix the proof-of-use documents before dispatch.
• Handle semi-finished goods separately: obtain an import licence under MDS-REQ 5 for production-purpose imports of semi-finished devices, and do not file them together with finished products.
• Run free-of-charge goods through the process: donations, exhibition samples and after-sales replacements fall under the Circulation definition; keep use statements and receiver records.
• Plan the first shipment backwards: from the shipping date derive MDMA approval, MDEL readiness and Saudi-DI data entry; reserve 90 days before expiry for renewal (practical estimate).
• Use official channels for hard cases: SFDA free technical support, call centre 19999 and md.rs@sfda.gov.sa; keep answers on file.

5. Verification checklist

• □ Current MDS-REQ 5 downloaded, release conditions and MDMA-exempt situations checked (practical estimate, pending verification)
• □ Importer’s MDEL activity scope covers the device categories and risk classes of this import
• □ MDMA certificate within validity, number and listing number traceable
• □ Model, brand name and legal manufacturer name and address identical word for word with the certificate
• □ UDI-DI data retrievable in Saudi-DI and consistent with labels
• □ Standard shipment pack complete, storage and transport records intact
• □ Special-use goods accompanied by proof-of-use documents
• □ Import licence obtained for semi-finished imports where applicable
• □ Free-of-charge goods brought under the Circulation definition
• □ First-shipment clearance milestone scheduled backwards, renewal reserving 90 days

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team coordinates Saudi Authorized Representative arrangements, import licences, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com